Joel D. Allen

7.1k total citations · 1 hit paper
46 papers, 2.5k citations indexed

About

Joel D. Allen is a scholar working on Radiology, Nuclear Medicine and Imaging, Virology and Molecular Biology. According to data from OpenAlex, Joel D. Allen has authored 46 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Radiology, Nuclear Medicine and Imaging, 19 papers in Virology and 18 papers in Molecular Biology. Recurrent topics in Joel D. Allen's work include Monoclonal and Polyclonal Antibodies Research (20 papers), HIV Research and Treatment (19 papers) and Glycosylation and Glycoproteins Research (12 papers). Joel D. Allen is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (20 papers), HIV Research and Treatment (19 papers) and Glycosylation and Glycoproteins Research (12 papers). Joel D. Allen collaborates with scholars based in United Kingdom, United States and Netherlands. Joel D. Allen's co-authors include Max Crispin, Yasunori Watanabe, Jason S. McLellan, Daniel Wrapp, Gemma E. Seabright, Andrew B. Ward, Maddy L. Newby, Thomas A. Bowden, Ian A. Wilson and Jayna Raghwani and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Joel D. Allen

43 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Site-specific glycan analysis of the SARS-CoV-2 spike

2020 1.0k citations Yasunori Watanabe, Joel D. Allen et al. Science profile →

Peers

Countries citing papers authored by Joel D. Allen

Since Specialization

Citations

This map shows the geographic impact of Joel D. Allen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel D. Allen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel D. Allen more than expected).

Fields of papers citing papers by Joel D. Allen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel D. Allen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel D. Allen. The network helps show where Joel D. Allen may publish in the future.

Co-authorship network of co-authors of Joel D. Allen

This figure shows the co-authorship network connecting the top 25 collaborators of Joel D. Allen. A scholar is included among the top collaborators of Joel D. Allen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel D. Allen. Joel D. Allen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Design and Immunogenicity of an HIV-1 Clade C Pediatric Envelope Glycoprotein Stabilized by Multiple Platforms 2025 ·Vaccines ·Sanjeev Kumar, Iván del Moral-Sánchez, (unknown), Maddy L. Newby, Joel D. Allen, Tom P. L. Bijl, (unknown), (unknown), Rakesh Lodha, Eric A. Ortlund, Max Crispin, Anamika Patel, (unknown), Kalpana Luthra	1
2	The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma 2025 ·Blood ·(unknown), Maddy L. Newby, Joel D. Allen, (unknown), Giorgia Chiodin, Patrick J. Duriez, John Butler, Katy J. McCann, David W. Scott, Ryan D. Morin, Kostiantyn Dreval, Andrew Davies, (unknown), Max Crispin, Francesco Forconi	0
3	From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks 2025 ·Proceedings of the National Academy of Sciences ·(unknown), (unknown), Annie Dosey, Joel D. Allen, Rebecca A. Gillespie, (unknown), Elizabeth M. Leaf, Max Crispin, Cole A. DeForest, Masaru Kanekiyo, Neil P. King	0
4	Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity 2024 ·Glycobiology ·(unknown), Tommy Tong, Emma T. Crooks, Keiko Osawa, (unknown), (unknown), Joel D. Allen, Max Crispin, James Μ. Binley	0
5	Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates 2023 ·Nature Communications ·Yi-Nan Zhang, (unknown), Aleksandar Antanasijevic, Joel D. Allen, (unknown), (unknown), Jeffrey Copps, Maddy L. Newby, Linling He, Deborah Chavez, (unknown), Anna Goodroe, John Dutton, Robert E. Lanford, Christopher Y. Chen, Ian A. Wilson, Max Crispin, Andrew B. Ward, Jiang Zhu	29
6	The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2 2023 ·Cell Reports ·Joel D. Allen, (unknown), Ge Song, Wanting He, Tazio Capozzola, Peter Yong, Dennis R. Burton, Raiees Andrabi, Max Crispin	18
7	Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization 2023 ·PLoS Pathogens ·Rajesh P. Ringe, Philippe Colin, Gabriel Ozorowski, Joel D. Allen, Anila Yasmeen, Gemma E. Seabright, Jeong Hyun Lee, Aleksandar Antanasijevic, Kimmo Rantalainen, Thomas J. Ketas, John P. Moore, Andrew B. Ward, Max Crispin, Per Johan Klasse	5
8	Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens 2023 ·Biotechnology Advances ·Maddy L. Newby, Joel D. Allen, Max Crispin	20
9	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers 2022 ·npj Vaccines ·Iván del Moral-Sánchez, Rebecca A. Russell, Edith E. Schermer, Christopher A. Cottrell, Joel D. Allen, Alba Torrents de la Peña, Celia C. LaBranche, Sanjeev Kumar, Max Crispin, Andrew B. Ward, David C. Montefiori, Quentin J. Sattentau, Kwinten Sliepen, Rogier W. Sanders	12
10	Preferential uptake of SARS-CoV-2 by pericytes potentiates vascular damage and permeability in an organoid model of the microvasculature 2022 ·Cardiovascular Research ·Abdullah O. Khan, Jasmeet S. Reyat, (unknown), Joshua H. Bourne, Martina Colicchia, Maddy L. Newby, Joel D. Allen, Max Crispin, Esther Youd, Paul G. Murray, Graham S. Taylor, Zania Stamataki, Alex Richter, Adam F. Cunningham, Matthew Pugh, Julie Rayes	20
11	Structure of the hepatitis C virus E1E2 glycoprotein complex 2022 ·Science ·Alba Torrents de la Peña, Kwinten Sliepen, Lisa Eshun-Wilson, Maddy L. Newby, Joel D. Allen, (unknown), Sylvie M. Koekkoek, (unknown), Max Crispin, Janke Schinkel, Gabriel C. Lander, Rogier W. Sanders, Andrew B. Ward	47
12	Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates 2021 ·Science Translational Medicine ·Lars Hangartner, (unknown), Eva G. Rakasz, Rebecca Nedellec, Nathanaël Hozé, (unknown), Maurício A. Martins, Gemma E. Seabright, Joel D. Allen, Andrea M. Weiler, Thomas C. Friedrich, Roland R. Regoes, Max Crispin, Dennis R. Burton	26
13	Suppression of O-Linked Glycosylation of the SARS-CoV-2 Spike by Quaternary Structural Restraints 2021 ·Analytical Chemistry ·(unknown), Joel D. Allen, Maddy L. Newby, Max Crispin	13
14	A cross-neutralizing antibody between HIV-1 and influenza virus 2021 ·PLoS Pathogens ·Chang‐Chun D. Lee, Yasunori Watanabe, Nicholas C. Wu, Julianna Han, Sonu Kumar, Tossapol Pholcharee, Gemma E. Seabright, Joel D. Allen, Chih-Wei Lin, Ji‐Rong Yang, Ming‐Tsan Liu, Chung‐Yi Wu, Andrew B. Ward, Max Crispin, Ian A. Wilson	23
15	Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens 2021 ·PLoS Pathogens ·Emma T. Crooks, (unknown), (unknown), E. Duggan, Jinsong Zhang, Kshitij Wagh, Huihui Mou, Joel D. Allen, (unknown), Keiko Osawa, Bette Korber, Yaroslav Tsybovsky, Evan M. Cale, John P. Nolan, Max Crispin, Laurent Verkoczy, James Μ. Binley	8
16	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation 2020 ·Nature Communications ·Yasunori Watanabe, Zachary T. Berndsen, Jayna Raghwani, Gemma E. Seabright, Joel D. Allen, Oliver G. Pybus, Jason S. McLellan, Ian A. Wilson, Thomas A. Bowden, Andrew B. Ward, Max Crispin	240
17	Site-specific glycan analysis of the SARS-CoV-2 spike breakdown → 2020 ·Science ·Yasunori Watanabe, Joel D. Allen, Daniel Wrapp, Jason S. McLellan, Max Crispin	1041
18	Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers 2018 ·Science ·Talar Tokatlian, Benjamin J. Read, Christopher A. Jones, Daniel W. Kulp, Sergey Menis, Jason Y.H. Chang, Jon M. Steichen, Sudha Kumari, Joel D. Allen, Eric L. Dane, Alessia Liguori, Maya Sangesland, Daniel Lingwood, Max Crispin, William R. Schief, Darrell J. Irvine	212
19	HIV-1 vaccine design through minimizing envelope metastability 2018 ·Science Advances ·Linling He, Sonu Kumar, Joel D. Allen, Deli Huang, Xiaohe Lin, Colin Mann, Karen L. Saye-Francisco, Jeffrey Copps, Anita Sarkar, (unknown), Gabriel Ozorowski, Devin Sok, Max Crispin, Andrew B. Ward, David Nemazee, Dennis R. Burton, Ian A. Wilson, Jiang Zhu	60
20	Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding 2018 ·Analytical Chemistry ·Yasunori Watanabe, Snežana Vasiljević, Joel D. Allen, Gemma E. Seabright, Helen M. E. Duyvesteyn, Katie J. Doores, Max Crispin, Weston B. Struwe	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact